

Title (en)
HETEROCYCLIC COMPOUND

Title (de)
HETEROCYCLISCHE VERBINDUNG

Title (fr)
COMPOSÉ HÉTÉROCYCLIQUE

Publication
EP 3239150 B1 20200205 (EN)

Application
EP 15873002 A 20151221

Priority
• JP 2014259662 A 20141224
• JP 2015085689 W 20151221

Abstract (en)
[origin: EP3239150A1] Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I) : wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

IPC 8 full level
C07D 471/04 (2006.01); **A61K 31/437** (2006.01); **A61K 31/4985** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **C07D 487/04** (2006.01)

CPC (source: EP US)
A61P 25/00 (2017.12 - EP US); **A61P 29/00** (2017.12 - EP US); **C07D 471/04** (2013.01 - EP US); **C07D 487/04** (2013.01 - EP US)

Cited by
US11952344B2; WO2021059017A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
EP 3239150 A1 20171101; **EP 3239150 A4 20180613**; **EP 3239150 B1 20200205**; JP 6675324 B2 20200401; JP WO2016104434 A1 20171005; US 10202376 B2 20190212; US 2017362223 A1 20171221; WO 2016104434 A1 20160630

DOCDB simple family (application)
EP 15873002 A 20151221; JP 2015085689 W 20151221; JP 2016566353 A 20151221; US 201515538297 A 20151221